Results 181 to 190 of about 2,325,434 (292)

Unmasking the silent epidemic: Mortality trends in diabetic nephropathy. [PDF]

World J Nephrol
Alvarez M.
europepmc   +1 more source

Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome.

HYPERTENSION, 2010
T. Fujita
semanticscholar   +1 more source

The Role of Aldosterone in Detecting Resistance-Driven Hypoaldosteronism and Deficit-Driven Hypoaldosteronism. [PDF]

J Clin Med
Ruiz-Sánchez JG, Calle-Pascual AL, Rubio-Herrera MÁ, De Miguel Novoa P, Gómez-Hoyos E, Runkle I.   +5 more
europepmc   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur, Aldo Bonaventura, Elena Osto, Stefano Ministrini, Simon Kraler, Petra Kleinbogard, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale   +13 more
wiley   +1 more source

Trained Immunity and Cardiovascular Risk: An Immunological Perspective

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Systemic inflammation is a key driver of atherogenesis and its complications. While anti‐inflammatory therapies targeting pathways such as IL‐1β and IL‐6 have shown promise in established atherosclerotic cardiovascular disease (ASCVD), potential systemic effects raise concerns about immune suppression and infection, underscoring the need for ...
Katherine A. Boden, Jason Chai, Tafadzwa T. J. Kufazvinei, Robin P. Choudhury   +3 more
wiley   +1 more source

Specialty grand challenge: existing issues and emerging frontiers in renal endocrinology. [PDF]

Front Endocrinol (Lausanne)
Haque ATME, Razzaque MS.
europepmc   +1 more source

Screening and Diagnosis of Primary Aldosteronism in Patients Using Renin‐Angiotensin System Inhibitors

The Journal of Clinical Hypertension, Volume 28, Issue 1, January 2026.
ABSTRACT This study investigated whether patients receiving renin‐angiotensin system inhibitors (RASIs) can undergo reliable screening for primary aldosteronism (PA) without discontinuation of therapy. Consecutive patients with hypertension who underwent PA screening at our hospital between 2016 and 2024 while on RASIs were recruited.
Qian Wang, Hui Dong, Hong‐Wu Li, Yu‐Bao Zou, Xiong‐Jing Jiang   +4 more
wiley   +1 more source

Protective association of renin‐angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure

Journal of Diabetes Investigation, Volume 17, Issue 1, Page 73-82, January 2026.
In heart failure, renin‐angiotensin system inhibitor (RASI) use was associated with less skeletal muscle wasting in patients with diabetes, but not in those without diabetes (significant interaction). The association in diabetes was more evident at lower plasma 3‐methylhistidine levels than at higher levels, suggesting a potential biomarker‐defined ...
Hidemichi Kouzu, Toshiyuki Yano, Satoshi Katano, Wataru Kawaharata, Ryo Numazawa, Ryohei Nagaoka, Hiroki Aida, Katsuhiko Ohori, Takefumi Fujito, Nobutaka Nagano, Masato Furuhashi   +10 more
wiley   +1 more source

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]

BMC Ophthalmol
Park JY, Jang Y, Hahn S.
europepmc   +1 more source